Related Articles
-
Earlier this year Grivennikov earned a separate five-year R01 grant from the NCI to determine the contribution of IL-17B/RB signaling to colorectal cancer and evaluate its mechanisms of action.
PHILADELPHIA (August 29, 2018)— Sergey Grivennikov, PhD, assistant professor in the Cancer Prevention and Control Program at Fox Chase Cancer Center, has received a R01 grant from the National Cancer Institute to support research on the connection between inflammation and colorectal cancer. The grant will provide approximately $280,000 per year over five years.
The Grivennikov laboratory studies the molecular and cellular mechanisms underlying how immune and inflammatory pathways promote tumor growth and progression. With this grant, they will seek to understand how inflammation regulates colorectal cancer progression.
The lab will conduct studies to define the contribution of IL-17B/RB signaling to colorectal cancer, and evaluate its mechanisms of action. A short-term goal is to establish a rationale for the specific inhibition of inflammation by targeting the IL-17RB pathway and to study basic mechanisms of cytokine signaling in cancer. The long-term goal is to propose improved colorectal cancer prevention and treatment practices based upon better understanding of molecular predictors of primary and recurrent metastasis.
“Despite important advances, colorectal cancer is the second leading cause of cancer-related death in the U.S.,” said Grivennikov. “We will use this funding to the best of our ability to understand the inflammatory causes of cancer progression, in order to improve outcomes.”
